- Home
- OS vs ZBIO Comparison
OS vs ZBIO Comparison
Compare OS & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OS
- ZBIO
- Stock Information
- Founded
- OS 2012
- ZBIO 2019
- Country
- OS United States
- ZBIO United States
- Employees
- OS N/A
- ZBIO N/A
- Industry
- OS
- ZBIO
- Sector
- OS
- ZBIO
- Exchange
- OS NYSE
- ZBIO NYSE
- Market Cap
- OS 6.7B
- ZBIO 389.2M
- IPO Year
- OS 2024
- ZBIO 2024
- Fundamental
- Price
- OS $25.03
- ZBIO $11.18
- Analyst Decision
- OS Strong Buy
- ZBIO Strong Buy
- Analyst Count
- OS 22
- ZBIO 7
- Target Price
- OS $32.15
- ZBIO $32.29
- AVG Volume (30 Days)
- OS 1.6M
- ZBIO 175.9K
- Earning Date
- OS 08-07-2025
- ZBIO 08-16-2025
- Dividend Yield
- OS N/A
- ZBIO N/A
- EPS Growth
- OS N/A
- ZBIO N/A
- EPS
- OS N/A
- ZBIO N/A
- Revenue
- OS $515,424,999.00
- ZBIO $15,000,000.00
- Revenue This Year
- OS $23.06
- ZBIO $206.00
- Revenue Next Year
- OS $20.15
- ZBIO $41.92
- P/E Ratio
- OS N/A
- ZBIO N/A
- Revenue Growth
- OS 26.83
- ZBIO N/A
- 52 Week Low
- OS $16.69
- ZBIO $5.83
- 52 Week High
- OS $35.39
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- OS N/A
- ZBIO N/A
- Support Level
- OS N/A
- ZBIO N/A
- Resistance Level
- OS N/A
- ZBIO N/A
- Average True Range (ATR)
- OS 0.00
- ZBIO 0.00
- MACD
- OS 0.00
- ZBIO 0.00
- Stochastic Oscillator
- OS 0.00
- ZBIO 0.00
About OS ONESTREAM INC
OneStream Inc is an AI-enabled and extensible software platform that unifies core financial functions and broader operational data and processes within a single platform. The Digital Finance Cloud of the company provides a comprehensive, dynamic, and predictive view of the entire enterprise, providing corporate leaders the control, visibility, and agility required to proactively adjust business and day-to-day execution.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.